Literature DB >> 31820212

Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.

Andrea V Barrio1, Stephanie Downs-Canner2, Marcia Edelweiss3, Kimberly J Van Zee2, Hiram S Cody2, Mary L Gemignani2, Melissa L Pilewskie2, George Plitas2, Mahmoud El-Tamer2, Laurie Kirstein2, Deborah Capko2, Sujata Patil4, Monica Morrow2.   

Abstract

BACKGROUND: In the ACOSOG (American College of Surgeons Oncology Group) Z0011 trial and the AMAROS (After Mapping of the Axilla: Radiotherapy or Surgery?) trial, matted nodes with gross extracapsular extension (ECE), a risk factor for locoregional recurrence, were an indication for axillary lymph node dissection (ALND), but the effect of microscopic ECE (mECE) in the sentinel lymph nodes (SLNs) on recurrence was not examined.
METHODS: Between 2010 and 2017, 811 patients with cT1-2N0 breast cancer and SLN metastasis were prospectively managed according to Z0011 criteria, with ALND for those with more than two positive SLNs or gross ECE. Management of mECE was not specified. In this study, we compare outcomes of patients with one to two positive SLNs with and without mECE, treated with SLN biopsy alone (n = 685).
RESULTS: Median patient age was 58 years, and median tumor size was 1.7 cm. mECE was identified in 210 (31%) patients. Patients with mECE were older, had larger tumors, and were more likely to be hormone receptor positive and HER2 negative, have two positive SLNs, and receive nodal radiation. At a median follow-up of 41 months, no isolated axillary failures were observed. There were 11 nodal recurrences; two supraclavicular ± axillary, four synchronous with breast, and five with distant failure. The five-year rate of any nodal recurrence was 1.6% and did not differ by mECE (2.3% vs. 1.3%; p = 0.84). No differences were observed in local (p = 0.08) or distant (p = 0.31) recurrence rates by mECE status.
CONCLUSIONS: In Z0011-eligible patients, nodal recurrence rates in patients with mECE are low after treatment with SLN biopsy alone, even in the absence of routine nodal radiation. The presence of mECE should not be considered a routine indication for ALND.

Entities:  

Mesh:

Year:  2019        PMID: 31820212      PMCID: PMC7145724          DOI: 10.1245/s10434-019-08104-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?

Authors:  B J Fisher; F E Perera; A L Cooke; A Opeitum; A R Dar; V M Venkatesan; L Stitt; J S Radwan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-06-01       Impact factor: 7.038

2.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Authors:  Mila Donker; Geertjan van Tienhoven; Marieke E Straver; Philip Meijnen; Cornelis J H van de Velde; Robert E Mansel; Luigi Cataliotti; A Helen Westenberg; Jean H G Klinkenbijl; Lorenzo Orzalesi; Willem H Bouma; Huub C J van der Mijle; Grard A P Nieuwenhuijzen; Sanne C Veltkamp; Leen Slaets; Nicole J Duez; Peter W de Graaf; Thijs van Dalen; Andreas Marinelli; Herman Rijna; Marko Snoj; Nigel J Bundred; Jos W S Merkus; Yazid Belkacemi; Patrick Petignat; Dominic A X Schinagl; Corneel Coens; Carlo G M Messina; Jan Bogaerts; Emiel J T Rutgers
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

3.  Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN.

Authors:  R F D van la Parra; P G M Peer; M F Ernst; K Bosscha
Journal:  Eur J Surg Oncol       Date:  2011-02-12       Impact factor: 4.424

4.  Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.

Authors:  Monica Morrow; Kimberly J Van Zee; Sujata Patil; Oriana Petruolo; Anita Mamtani; Andrea V Barrio; Deborah Capko; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Laurie Kirstein; Melissa Pilewskie; George Plitas; Virgilio S Sacchini; Lisa M Sclafani; Alice Ho; Hiram S Cody
Journal:  Ann Surg       Date:  2017-09       Impact factor: 12.969

5.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Authors:  Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

6.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Authors:  Armando E Giuliano; Karla V Ballman; Linda McCall; Peter D Beitsch; Meghan B Brennan; Pond R Kelemen; David W Ollila; Nora M Hansen; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow
Journal:  JAMA       Date:  2017-09-12       Impact factor: 56.272

7.  Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy.

Authors:  C Leonard; M Corkill; J Tompkin; B Zhen; D Waitz; L Norton; J Kinzie
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

Review 8.  Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis.

Authors:  A Nottegar; N Veronese; M Senthil; R M Roumen; B Stubbs; A H Choi; N C Verheuvel; M Solmi; A Pea; P Capelli; M Fassan; G Sergi; E Manzato; M Maruzzo; F Bagante; M Koç; M A Eryilmaz; E Bria; L Carbognin; F Bonetti; M Barbareschi; C Luchini
Journal:  Eur J Surg Oncol       Date:  2016-03-10       Impact factor: 4.424

9.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.

Authors:  Armando E Giuliano; Karla Ballman; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Monica Morrow; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

10.  Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.

Authors:  Sura Aziz; Elisabeth Wik; Gøril Knutsvik; Tor Audun Klingen; Ying Chen; Benedicte Davidsen; Hans Aas; Turid Aas; Lars A Akslen
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

View more
  4 in total

Review 1.  Regional Nodal Management in the Setting of Up-Front Surgery.

Authors:  Lior Z Braunstein; Monica Morrow
Journal:  Semin Radiat Oncol       Date:  2022-07       Impact factor: 5.421

2.  The Attitudes of Brazilian Breast Surgeons on Axillary Management in Early Breast Cancer-10 Years after the ACOSOG Z0011 Trial First Publication.

Authors:  Eduardo Camargo Millen; Francisco Pimentel Cavalcante; Felipe Zerwes; Guilherme Novita; Alessandra Borba Anton de Souza; João Henrique Penna Reis; Helio Rubens de Oliveira Filho; Luciana Naíra de B L Limongi; Barbara Pace Silva de Assis Carvalho; Adriana Magalhães de Oliveira Freitas; Monica Travassos Jourdan; Vilmar Marques de Oliveira; Ruffo Freitas-Junior
Journal:  Ann Surg Oncol       Date:  2021-09-27       Impact factor: 5.344

3.  Survival and recurrence with or without axillary dissection in patients with invasive breast cancer and sentinel node metastasis.

Authors:  Vanessa Monteiro Sanvido; Simone Elias; Gil Facina; Silvio Eduardo Bromberg; Afonso Celso Pinto Nazário
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

4.  A National Survey of Breast Surgeons and Radiation Oncologists on Contemporary Axillary Management in Mastectomy Patients.

Authors:  Chandler S Cortina; Carmen Bergom; Morgan Ashley Craft; British Fields; Ruta Brazauskas; Adam Currey; Amanda L Kong
Journal:  Ann Surg Oncol       Date:  2021-07-10       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.